Tuan S. Nguyen

TL;DR: Abemaciclib represents the first selective inhibitor of CDK4 and CDK6 with a safety profile allowing continuous dosing to achieve sustained target inhibition, and this first-in-human experience demonstrates single-agent activity for patients with advanced breast cancer, NSCLC, and other solid tumors.

TL;DR: The primary endpoint was met; low nuclear TS expression was associated with longer PFS; further randomized studies are needed to explore nuclear TS IHC expression as a potential biomarker of clinical outcomes for pemetrexed treatment in larger patient cohorts.

TL;DR: Cixutumumab (10 mg/kg) with or without antiestrogen q2w had an acceptable safety profile, but no significant clinical efficacy, and the prognostic or predictive value of IR as a biomarker for IGF-1R–targeted therapies requires further validation.

TL;DR: Although generally well tolerated, PFS was not improved during treatment with tabalumab compared to placebo, and BAFF appears to have some prognostic value in patients with multiple myeloma.

TL;DR: The PCE combination increased PFS, but it was not significantly superior to PC in this phase II study, indicating the importance of optimal debulking with regard to PFS.